Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / Cadila Healthcare gets WHO warning for its Moraiya vaccine plant in Gujarat
BackBack

Cadila Healthcare gets WHO warning for its Moraiya vaccine plant in Gujarat

The world body, in its inspection from 26-30 October, found data integrity issues at the plant that manufactures Lyssavac-N, an anti-rabies vaccine

Cadila said it has responded to WHO and has been implementing remedial measures at the Gujarat plant. Photo: iStockPremium
Cadila said it has responded to WHO and has been implementing remedial measures at the Gujarat plant. Photo: iStock

Hyderabad: Drug maker Cadila Healthcare Ltd on Tuesday said it has received a Notice of Concern (NoC) or warning from the World Health Organisation (WHO) for violations of good manufacturing practices at its vaccine plant in Moraiya in Sanand district of Gujarat.

The world body, in its inspection from 26-30 October, found data integrity issues at the plant that manufactures Lyssavac-N, an anti-rabies vaccine.

The vaccine plant is located in the vicinity of the formulation facility that received a US Food and Drug Administration (FDA) warning letter on 31 December over non-compliance with manufacturing standards.

Cadila said it has responded to WHO and has been implementing remedial measures. “There is no significant impact on the business and there were no exports of this product to the US," the company clarified.

Cadila stopped production, initiated an internal investigation and made a voluntary recall of all the batches of Lyssavac-N made after April 2015, from when the investigation revealed that the issues started.

The company has also informed WHO that the manufacturing activities for vaccines and biologicals at this site will only resume after acceptable corrective and preventive actions (CAPAs) have been submitted, assessed and confirmed through an on-site inspection.

Cadila has got WHO approval to sell Lyssavac-N to United Nations agencies. The vaccine is marketed in India under the brand name Vaxirab.

WHO issues such warnings when it finds violations of good manufacturing practices at a site that produces products prequalified by it.

An NoC may withhold pre-qualification of all new products manufactured at the site until observations have been satisfactorily addressed. Failure to do so within a reasonable time frame may lead to suspension of procurements of all prequalified products made at the site.

Shares of Cadila dropped 5.29% to close at 323.20 on the BSE, while the benchmark Sensex gained 0.18% to end 25330.49 points.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 22 Mar 2016, 11:26 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie